human papillomavirus – Page 20

Alberta committee suggests free HPV vaccine for boys

Source: CBC News Cost to the province estimated between $5 million and $8 million The province is considering offering boys free immunizations against the human papillomavirus. The HPV vaccination is currently offered on a voluntary basis to all girls in Alberta entering Grade 5. The vaccine is said to prevent 70 per cent of cervical cancers, according to Alberta Health and Wellness. Two strains of HPV are also thought to be a cause of anal, penile and oral cancers. Susan Morgan's husband was diagnosed with Stage 4 oral cancer, which they later found out was caused by the HPV virus. She has been lobbying to have the vaccine for boys covered by the province and was astounded the HPV vaccination was only free for girls. Morgan says the effects of the radiation and chemotherapy treatment for the cancer were horrific. "You have open sores in your mouth,” she said. “You start to lose your ability to swallow; you end up on a feeding tube." Free vaccine for boys recommended A report by an advisory committee in Alberta recommends extending HPV coverage to boys. Chief medical officer Dr. Andre Corriveau says that would cost between $5 million and $8 million. Now he'll review the report and advise the province by the end of the month. "I have a responsibility right now to make sure our system has the capacity to deliver," he said. But, for the Morgans, waiting is not an option and they have decided to pay hundreds of dollars [...]

Charlotte Parker2012-05-07T13:25:56-07:00May, 2012|Oral Cancer News|

New method of predicting the spread of throat cancer to other body parts found

Source: starglobaltribune.com Author: staff Independent of other factors, such as smoking history and HPV status, matted lymph nodes appear to signal increased chance of oropharyngeal cancer spreading to other parts of the body. Researchers at the University of Michigan Health System have found a new indicator that may predict which patients with a common type of throat cancer are most likely have the cancer spread to other parts of their bodies. Patients with oropharyngeal squamous cell carcinoma who had “matted” lymph nodes – nodes that are connected together – had a 69 percent survival rate over three years, compared to 94 percent for patients without matted nodes, according to a study published online ahead of print publication in Head & Neck. The oropharynx is an area that includes the back of the tongue, soft palate, throat and tonsils. “The spread of cancer throughout the body accounts for about 45 percent of the deaths from oropharyngeal carcinoma,” says the study’s senior author, Douglas B. Chepeha, M.D., M.S.P.H., an associate professor of otolaryngology head and neck surgery at the U-M Medical School. “Our findings may help doctors identify patients who are at higher risk for having their cancer metastasize and who would benefit from additional systemic therapy. Conversely, some patients without matted nodes may benefit from a reduction of the current standard treatment, which would cut down on uncomfortable side effects.” Notably, the findings indicate an increased risk independent of other established prognostic factors, such as the patient’s history of smoking or [...]

Oral Cancer Foundation News Team - A2012-05-07T08:16:13-07:00May, 2012|Oral Cancer News|

CDC report releases updated information on HPV-associated cancers

Source: www.dentistryiq.com Author: staff The Centers for Disease Control and Prevention released on April 24, 2012, an updated statistical count on the prevalence of HPV-associated cancers in the United States. Oropharyngeal cancers, primarily the base of the tongue and tonsils, were the second most common after cervical cancer. Published in the April 20 edition of CDC’s Morbidity and Mortality Weekly Report (MMWR), the report, titled, ”Human Papillomavirus-Associated Cancers — United States, 2004–2008,” provides updated information from an analysis of data for all 50 states and the District of Columbia from the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology and End Results (SEER) program. An average of 33,369 HPV-associated cancers were diagnosed annually (rate = 10.8 per 100,000 population), including 11,726 cases of oropharyngeal cancers. CDC estimates that about 7,400—63%—of the cases of oropharyngeal cancer each year were attributable to HPV infection. These cancers were found three times more frequently among men. The Centers for Disease Control and Prevention released on April 24, 2012, an updated statistical count on the prevalence of HPV-associated cancers in the United States. Oropharyngeal cancers, primarily the base of the tongue and tonsils, were the second most common after cervical cancer. Published in the April 20 edition of CDC’s Morbidity and Mortality Weekly Report (MMWR), the report, titled, ”Human Papillomavirus-Associated Cancers — United States, 2004–2008,” provides updated information from an analysis of data for all 50 states and the District of Columbia from the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology and [...]

Oral Cancer Foundation News Team - A2012-04-25T06:40:59-07:00April, 2012|Oral Cancer News|

Mouthing off against oral cancer

Source: www.marketwatch.com Author: staff April Is Oral Cancer Awareness Month According to the Centers for Disease Control and Prevention (CDC), more than 30,000 new cases of oral cancer are diagnosed each year, and more than 8,000 deaths occur annually. The five-year survival rate for oral cancers is roughly 50 percent. In observance of Oral Cancer Awareness Month, the Academy of General Dentistry (AGD) recommends that patients receive a dental exam from a general dentist every six months. Dental exams not only help to decrease a patient's risk of oral diseases, such as cavities and periodontal (gum) disease, but they also may help to diagnose other, sometimes life-threatening, medical conditions, such as oral cancer. "The next time you visit your dentist, ask about an oral cancer screening," says AGD spokesperson Seung-Hee Rhee, DDS, FAGD. "Your dentist will feel for lumps or irregular tissue changes in your neck, head, cheeks, and oral cavity and thoroughly examine the soft tissues in your mouth, specifically looking for any sores or discolored tissues. Although you may have already been receiving this screening from your dentist, it's a good idea to confirm that this screening is a part, and will remain a part, of your regular exam." Although oral cancer is sometimes difficult to self-diagnose, warning signs may include bleeding sores; sores that do not heal; lumps; thick, hard spots; soreness or feeling that something is caught in the throat; difficulty chewing or swallowing; ear pain; difficulty moving the jaw or tongue; hoarseness; and numbness of [...]

Oral Cancer Foundation News Team - A2012-03-30T05:19:13-07:00March, 2012|Oral Cancer News|

New indicator may help Identify patients with increased risk from throat cancer

Source: www.onclive.com Author: staff Patients with oropharyngeal squamous cell carcinoma who had "matted" lymph nodes -- nodes that are connected together -- are more likely to metastasize than those without matted lymph nodes, according to a study published online in the journal Head & Neck. Metastases account for about 45% of the deaths among patients with oropharyngeal carcinoma, wrote Douglas B. Chepeha, MD, MPH, an associate professor of Otolaryngology Head and Neck Surgery at the University of Michigan Medical School in Ann Arbor. "Our findings may help doctors identify patients who are at higher risk for having their cancer metastasize and who would benefit from additional systemic therapy," he said, adding that the opposite was also true -- those without matted nodes might benefit from reducing therapy. The researchers tracked 78 patients who were part of a clinical trial evaluating 2 cancer drugs with intensity-modulated radiation therapy. All of the treatment-naive patients had stage III-IV squamous cell carcinoma of the oropharynx. Sixteen of the 78 patients had matted nodes. They found that patients with matted nodes had a 69% survival rate over 3 years, compared with 94% for patients without matted nodes. The risk was independent of other prognostic factors, such as the patient's history of smoking, alcohol use, or human papillomavirus (HPV) infection. Matted nodes appear to be an especially strong indicator of increased risk among patients who are HPV-positive. However, HPVpositive patients had better overall outcomes than HPV-negative patients did. The patients with the best outcomes were HPV-positive [...]

Oral Cancer Foundation News Team - A2012-03-19T07:12:42-07:00March, 2012|Oral Cancer News|

Epidermal Growth Factor Receptor and the Changing Face of Oropharyngeal Cancer

Source: Journal of Clinical Oncology To the Editor: In their article, Chaturvedi et al1 document the rise in human papillomavirus (HPV) –associated cancers as a proportion of squamous cell carcinomas of the oropharynx over the last 25 years. The contemporary figures are mirrored by two recent British studies2,3 demonstrating that the majority of oropharyngeal cancers are now HPV related. In the accompanying editorial,4 Mroz et al rightly highlight the importance of evaluating HPV vaccination for both men and women in the light of these data and lament the lack of significant improvement in the outcomes for non–HPV-associated head and neck cancers. However, they also suggest that the benefit of targeting epidermal growth factor receptor (EGFR) through concurrent cetuximab may be confined to HPV-associated tumors. Although EGFR expression per se does not correlate closely with response to cetuximab, there is increasing evidence of an inverse correlation between p16INK4A expression (as a marker of HPV association) and EGFR expression shown by immunohistochemistry.5,6 Though suppressed by viral oncogenes, HPV-associated tumors retain wild-type P53,7 and patients with this tumor type have demonstrated excellent survival with existing protocols such as concurrent chemoradiotherapy or surgery with postoperative radiotherapy. Conversely, non-HPV tumors, harboring a range of mutations,8 may respond less well to DNA-damaging agents, but patients with these tumors might benefit from the addition of concurrent EGFR blockade to radiotherapy. Data from the recent SPECTRUM (Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer) study of adding another EGFR-targeting monoclonal antibody, panitumumab,9 [...]

Charlotte Parker2012-03-09T10:34:29-07:00March, 2012|Oral Cancer News|

HPV exposure increases men’s risk of cancer

Source: http://news.medill.northwestern.edu/ Author: Zen Vuong “We’re at the precipice of this epidemic,” said Dr. Ezra Cohen, who specializes in head and neck cancers. The culprit is sexually-transmitted human papillomavirus-16. Human papillomavirus-positive head and neck cancer cases have been rising about 3 percent every year for the last three decades, said Cohen of The University of Chicago Medicine, an institution that includes the University of Chicago Hospitals. HPV-16 infection is three times more likely in men than in women, he added. Cells of the upper respiratory system of both men and women are very similar to the surface of the cervix in women, said Dr. Kenneth Alexander, chief of infectious diseases at The University of Chicago Medicine. HPV is linked to cervical cancer as well. The Centers for Disease Control and Prevention estimates 10,800 new cases of HPV-associated cervical cancer in the United States each year. This number is nearly 35 percent larger than the 7,100 cases of HPV-associated head and neck cancers found in the United States each year. Oral sex is “probably the most important risk factor” in contracting HPV-16-related head and neck cancer, which “will become more common than cervical cancer in this decade,” he added. Some 5,600 men are diagnosed with HPV-associated head and neck cancers each year, whereas only 1,500 women suffer the same fate, according to the CDC. HPV-16, one of more than 150 strains, is a sexually transmitted condition. More than 40 HPV types can be sexually transmitted, according to the National Cancer Institute. [...]

Oral Cancer Foundation News Team - A2012-03-07T15:30:30-07:00March, 2012|Oral Cancer News|

Canadian provinces weighing HPV vaccination of boys

Source: www.cmaj.ca/ Author: Laura Eggertson Provinces weighing the merits of implementing the National Advisory Committee on Immunization's recommendation to offer human papillomavirus (HPV) vaccine to boys and men aged 9–26 are facing a tricky trade-off between benefits and costs. “I think the benefits are there, but the costs are high,” which is a crucial issue for publicly funded programs, says Dr. Monika Naus, medical director of immunization programs and vaccine-preventable diseases for the British Columbia Centre for Disease Control. The National Advisory Committee on Immunization last month recommended extending the human papillomavirus vaccine to boys and men aged 9 to 26 “for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2, and 3, anal cancer, and anogenital warts”. The move followed on the heels of an October 2011 recommendation from United States Centers for Disease Control and Prevention advisory panel recommendation that HPV vaccine be given to boys aged 11–12 to ward off genital warts, anal cancer and “possibly” head and neck cancer. In deciding whether to proceed, the provinces should note that “the public health and economic burden of AGWs [anogenital warts] in Canada is considerable, particularly among men whose incidence rates and incidence rate ratios compared to females have been increasing in recent years,” the committee stated. The committee’s report also noted that the number of annual cases (and average annual incidence per 100 000) of penile cancer among men in Canada is 127.4 (1.0 per 100 000), while the number for cancer of the anus is [...]

Oral Cancer Foundation News Team - A2012-02-26T10:01:29-07:00February, 2012|Oral Cancer News|

CD4 counts predict chemo response in laryngeal cancer

Source: www.oncologyreport.com/ Author: Miriam E. Tucker Pretreatment CD4 levels predicted response to induction chemotherapy among 97 patients with advanced laryngeal cancer, but not for 66 patients with advanced oropharyngeal cancer, according to a retrospective analysis of data from two clinical trials. The two groups of head and neck cancer patients were enrolled in two identical prospective, phase II trials of induction chemotherapy and organ preservation, in which tumor response after one cycle of cisplatin and 5-fluorouracil was used to select those who would undergo surgery or definitive chemoradiation (J. Clin. Oncol. 2006;24:593-8 in laryngeal cancer; J. Clin. Oncol. 2008;26:3138-46 in oropharyngeal cancer). Several lymphocyte subsets were measured before treatment via routine flow cytometry in peripheral blood in the laryngeal cancer patients, but only CD4 (helper cell) levels were significantly associated with chemotherapy response. Both absolute CD4 counts and CD4 percentages were higher among induction chemotherapy responders than nonresponders (P = .006 and P = .04, respectively). Investigators also saw a trend for responders to have an increased percentage of CD3 cells (P = .13), decreased percentage of CD8 cells (P = .11), and higher CD4/CD8 ratios. "Host immune parameters are important factors in treatment outcome, and may be useful in identifying subsets of patients with cancers that are responsive to organ-preserving therapy," said Dr. Gregory T. Wolf, who presented the data at a head and neck cancer symposium sponsored by the American Society for Radiation Oncology. "It is likely that immunobiology of head and neck cancers differ significantly by tumor [...]

Oral Cancer Foundation News Team - A2012-02-26T09:53:59-07:00February, 2012|Oral Cancer News|

Oral Sex Cancer Virus More Common in Men Than Women, Study Finds

Source: Bloomberg.com About 10 percent of men and 3.6 percent of women are orally infected with human papillomavirus, which is acquired through oral sex and can cause cancer. There are two peaks in the age people are infected -- 30 to 34 and 60 to 64, according to the study published today in the Journal of the American Medical Association. The virus is linked to throat cancer, and is becoming a more common cause of the disease as Americans quit smoking. The virus, called HPV, is the most-common sexually transmitted virus in the U.S., where half the population will be infected at some time in their lives, according to the Centers for Disease Control and Prevention. It is known to cause cervical, vulvar, vaginal, penile and anal cancer. The higher HPV infection rate in men explains why their head and neck cancer rates are greater, said Maura Gillison, a professor at the Ohio State University College of Medicine in Columbus. “This provides pretty strong evidence that the higher infection rate is the reason why,” said Gillison, the study’s lead author, in a telephone interview. “This is a jumping board for additional research.” Besides sex, other demographics associated with oral HPV infection include age, lifetime number of sex partners, and the number of cigarettes smoked each day. The research is the first population-based study to examine how many men and women were infected, Gillison said. Existing Vaccines Though Merck & Co.’s Gardasil and GlaxoSmithKline Plc (GSK)’s Cervarix target genital HPV, it’s [...]

Charlotte Parker2012-01-26T10:10:18-07:00January, 2012|Oral Cancer News|